Evidence map›Paper›PMID 36177008›Full record

ArticleFrontiers in immunology2022

Global alteration of colonic microRNAome landscape associated with inflammatory bowel disease.

Éva Boros, Zoltán Hegedűs, Zoltán Kellermayer, Péter Balogh, István Nagy

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Éva BorosSeqomics Biotechnology Ltd., Mórahalom, Hungary.
Zoltán HegedűsInstitute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network, Szeged, Hungary.
Zoltán KellermayerDepartment of Immunology and Biotechnology, University of Pécs, Pécs, Hungary.
Péter BaloghDepartment of Immunology and Biotechnology, University of Pécs, Pécs, Hungary.
István NagySeqomics Biotechnology Ltd., Mórahalom, Hungary.
University of Pecs · HUHungarian Research NetworkHUN-REN Szegedi Biológiai Kutatóközpont · HUSeqOmics Biotechnology (Hungary) · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory Bowel Disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract that associates with, among others, increased risk of colorectal cancer. There is a growing evidence that miRNAs have important roles in pathological processes, such as inflammation or carcinogenesis. Understanding the molecular mechanisms such as alterations in microRNAome upon chronic intestinal inflammation is critical for understanding the exact pathomechanism of IBD. Hence, we conducted a genome wide microRNAome analysis by applying miRNA-Seq in a rat model of experimental colitis, validated the data by QPCR, examined the expression of a selection of precursor and mature miRNAs, performed in depth biological interpretation using Ingenuity Pathway Analysis and tested the obtained results on samples derived from human patients. We identified specific, interdependent expression pattern of activator/repressor transcription factors, miRNAs and their direct targets in the inflamed colon samples. Particularly, decreased expression of the miR-200 family members (miR-200a/b/c,-141, and -429) and miR-27b correlates with the reduced level of their enhancers (HNF1B, E2F1), elevated expression of their repressors (ZEB2, NFKB1) and increased expression of their target genes (ZEB2, RUNX1). Moreover, the marked upregulation of six miR-27b target genes (IFI16, GCA, CYP1B1, RUNX1, MEF2C and MMP13) in the inflamed colon tissues is a possible direct consequence of the lack of repression due to the downregulated miRNA-27b expression. Our data indicate that changes in microRNAome are associated with the pathophysiology of IBD, consequently, microRNAs offer potential targets for the diagnosis, prognosis and treatment of IBD.

Indexed as

Inflammatory Bowel DiseasesMicroRNAsAnimalsColonCore Binding Factor Alpha 2 SubunitHumansInflammationMatrix Metalloproteinase 13RatsCore Binding Factor Alpha 2 SubunitMatrix Metalloproteinase 13MicroRNAsCrohn’s disease (CD)inflammatory bowel disease (IBD)microRNA-seqnon-coding RNAsulcerative colitis (UC)

Identifiers

PMID36177008
PMCPMC9513375
OpenAlexW4296017873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.